Daily Medication Pearl: Trastuzumab
Trastuzumab (Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant) is a HER2/neu receptor antagonist indicated for early and advanced breast cancer, advanced stomach cancer, and gastroesophageal junction cancer.
Medication Pearl of the Day: Trastuzumab
Indication: Trastuzumab (Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant) is a HER2/neu receptor antagonist indicated for the treatment of HER2-overexpressing new or metastatic breast cancer; alone or in combination with other cancer medicines such as carboplatin, cyclophosphamide, docetaxel, doxorubicin, and paclitaxel. Trastuzumab injection is also used in combination with cisplatin and capecitabine or 5-fluorouracil to treat HER2-overexpressing metastatic stomach and gastroesophageal cancers.
- Dosage forms: For injection 420 mg lyophilized powder in a multiple-dose vial for reconstitution.
- Adverse events: Most common adverse reactions (≥ 5%) are headache, diarrhea, nausea, and chills.
- Mechanism of action: The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Trastuzumab products have been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2.
- Manufacturer: Mylan